Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Psychosis: Goals of Pharmacotherapy

Psychosis: Goals of Pharmacotherapy

Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.

Drug Therapy

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications

Preclinical Development: Overview

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...

Clinical Trials: Overview

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...

Drug Regulation

Drug Regulation

Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...

Psychosurgery

Psychosurgery

Psychosurgery, the surgical alteration or permanent removal of brain tissue to alleviate severe psychological conditions, stands as one of the most radical and controversial treatments in the history of mental health care. Its development and application have evolved significantly, marked by dramatic shifts in scientific understanding and ethical perspectives.
Historical Development of Psychosurgery
In the 1930s, Portuguese neurologist Antonio Egas Moniz introduced a surgical procedure designed...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Narrative exposure therapy for post-traumatic stress symptoms in women who are incarcerated: an open pilot study.

European journal of psychotraumatology·2026

Same author

Machine learning models to detect opioid misuse in emergency department patients at triage.

The American journal of emergency medicine·2026

Same author

Improving post-traumatic stress symptoms in homeless-experienced women using narrative exposure therapy: a single-arm, open pilot study.

European journal of psychotraumatology·2026

Same author

Machine learning models to detect opioid misuse in Emergency Department patients at triage.

medRxiv : the preprint server for health sciences·2025

Same author

Trends in Fomepizole Use for Acetaminophen Poisoning in the United States; 2013-2024.

Journal of medical toxicology : official journal of the American College of Medical Toxicology·2025

Same author

Socioeconomic and Demographic Disparities in Keratoconus Treatment.

American journal of ophthalmology·2024

Search research articles

Related Experiment Video

Updated: Mar 6, 2026

Development of a Virtual Reality Assessment of Everyday Living Skills

Development of a Virtual Reality Assessment of Everyday Living Skills

Published on: April 23, 2014

Ethical challenges in developing drugs for psychiatric disorders.

Felix Carrier¹, David Banayan², Randy Boley²

¹Department of Psychiatry, Université Laval, Quebec, Canada.

Progress in Neurobiology

|March 8, 2017

Summary

Advancing mental disorder classification with the Research Domain Criteria (RDoC) necessitates addressing ethical challenges in psychiatric drug development. Collaborative research and transparent practices are crucial for creating effective and ethical treatments.

Keywords:

Ethics Neuroethics Pharmaceuticals Research design

More Related Videos

Developing a Rat Model for Bipolar Disorder

Developing a Rat Model for Bipolar Disorder

Published on: May 2, 2025

Ole Isacson: Development of New Therapies for Parkinson's Disease

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

Related Experiment Videos

Last Updated: Mar 6, 2026

Development of a Virtual Reality Assessment of Everyday Living Skills

Development of a Virtual Reality Assessment of Everyday Living Skills

Published on: April 23, 2014

Developing a Rat Model for Bipolar Disorder

Developing a Rat Model for Bipolar Disorder

Published on: May 2, 2025

Ole Isacson: Development of New Therapies for Parkinson's Disease

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

Area of Science:

Psychiatry
Neuroscience
Bioethics

Background:

The National Institute of Mental Health (NIMH) Research Domain Criteria (RDoC) promotes a disease model for mental disorder classification.
This shift aims for improved neurobiological understanding and reduced diagnostic variability in treatment efficacy.
However, this paradigm shift introduces significant ethical considerations in psychiatric drug development.

Purpose of the Study:

To identify and discuss the multifaceted ethical issues arising from the RDoC framework in psychiatric drug development.
To emphasize the need for collaborative, stakeholder-informed approaches to address these ethical challenges.
To highlight the importance of research integrity, resource allocation, and patient-centered considerations.

Main Methods:

The study is a conceptual analysis and ethical review of current trends in psychiatric drug development.
It synthesizes ethical challenges related to informed consent, funding, research design, and special populations.
It draws upon the principles and implications of the RDoC framework.

Main Results:

Ethical challenges extend beyond traditional concerns to include research models, design quality, and resource justification.
Clinical innovation and the inclusion of special populations present unique ethical imperatives.
Future ethical considerations will involve genetic markers, personalized medicine, and funding tensions.

Conclusions:

Collaborative scientific inquiry involving diverse stakeholders is essential for addressing ethical complexities in psychiatric drug development.
Innovations in clinical trial design are needed to align with real-world clinical practices.
Enhanced transparency in consent, careful attention to suicidality, and dedicated support for special populations are vital for developing sound psychiatric therapies.